Ocugen
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2013-01-01
- Employees
- 65
- Market Cap
- $382.8M
- Website
- http://www.ocugen.com
- Introduction
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.
Clinical Trials
11
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Expanded Access Program for RP in Adults
- Conditions
- Retinitis Pigmentosa
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2025-07-28
- Lead Sponsor
- Ocugen
- Registration Number
- NCT06574997
- Locations
- 🇺🇸
Associated Retina Consultants, Phoenix, Arizona, United States
🇺🇸Advanced Research, Deerfield Beach, Florida, United States
🇺🇸Erie Retina Research, Erie, Pennsylvania, United States
A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa
- Conditions
- Retinitis Pigmentosa
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2025-08-03
- Lead Sponsor
- Ocugen
- Target Recruit Count
- 150
- Registration Number
- NCT06388200
- Locations
- 🇨🇦
Research Institute of the McGill University Health Centre, Montréal, Quebec, Canada
🇺🇸Associated Retina Consultants, Phoenix, Arizona, United States
🇺🇸University of Southern Califormia, La Jolla, California, United States
Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy
- Conditions
- Geographic Atrophy
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Ocugen
- Target Recruit Count
- 60
- Registration Number
- NCT06018558
- Locations
- 🇺🇸
Advanced Research, LLC, Coral Springs, Florida, United States
🇺🇸The Retina Institute, Saint Louis, Missouri, United States
🇺🇸Valley retina Institute, McAllen, Texas, United States
A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease
- First Posted Date
- 2023-07-21
- Last Posted Date
- 2025-07-29
- Lead Sponsor
- Ocugen
- Target Recruit Count
- 51
- Registration Number
- NCT05956626
- Locations
- 🇺🇸
Vitreo Retinal Associates, P.A., Gainesville, Florida, United States
🇺🇸Advanced Research, LLC, Pompano Beach, Florida, United States
🇺🇸Retina Partners Midwest, P.C., Carmel, Indiana, United States
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
- Conditions
- Center Involved Diabetic Macular EdemaDiabetic Macular Edema
- Interventions
- First Posted Date
- 2023-04-06
- Last Posted Date
- 2025-08-06
- Lead Sponsor
- Ocugen
- Target Recruit Count
- 30
- Registration Number
- NCT05802329
- Locations
- 🇺🇸
Advanced Research LLC, Deerfield Beach, Florida, United States
🇺🇸Erie Retina Research, LLC, Erie, Pennsylvania, United States
🇺🇸Retina Consultants of Texas Research Centers, Bellaire, Texas, United States
- Prev
- 1
- 2
- 3
- Next
News
Stargardt Disease Pipeline Shows Promising Progress with Multiple Gene Therapies Advancing to Late-Stage Trials
Ocugen's OCU410ST gene therapy has received FDA approval to launch a Phase 2/3 pivotal confirmatory trial for treating all forms of Stargardt disease, with the potential to serve as the foundation for a biologics license application.
Carisma Therapeutics and OrthoCellix Announce $25M Merger to Advance Phase 3 Knee Cartilage Therapy
Carisma Therapeutics and OrthoCellix have entered into a definitive merger agreement to create a Nasdaq-listed regenerative cell therapy company focused on orthopedic diseases.
Ocugen Secures $161M Gene Therapy Licensing Deal for OCU400 in Korean Market
Ocugen signed a binding term sheet with a Korean pharmaceutical leader for exclusive rights to OCU400, a novel modifier gene therapy for retinitis pigmentosa, potentially worth over $161 million.
OCU410 Gene Therapy Shows Promise for Geographic Atrophy with Single-Dose Treatment Approach
OCU410 gene therapy demonstrated a 21.4% reduction in geographic atrophy lesion growth in low-dose patients after 6 months compared to untreated fellow eyes.
Three Pharmaceutical Companies Advance Next-Generation COVID-19 Therapeutics in Clinical Trials
INOVIO Pharmaceuticals reports promising Phase I results for its DMAbs technology, showing 100% of subjects maintained relevant antibody levels with no serious adverse events.
Opthia Faces $1 Billion Investor Obligation Following Sozinibercept Trial Failure in WetAMD
Opthia may owe up to $1 billion to investors following the failure of sozinibercept in clinical trials for wet age-related macular degeneration (WetAMD).
WashU's Novel Nasal COVID-19 Vaccine Advances to U.S. Phase 1 Clinical Trials
FDA approves Ocugen's investigational new drug application for a nasal COVID-19 vaccine, developed at Washington University in St. Louis, advancing to Phase 1 clinical trials this spring.
Ocugen's Inhaled COVID-19 Vaccine Candidate, OCU500, Advances to Phase 1 Trial After FDA Review
Ocugen's OCU500, a novel inhaled mucosal vaccine for COVID-19, has received IND clearance from the FDA, allowing a Phase 1 clinical trial to proceed.
Dry AMD Therapeutic Pipeline Shows Promise with 70+ Companies Advancing Novel Therapies
The dry age-related macular degeneration (AMD) therapeutic landscape is robust, with over 70 companies developing more than 80 therapies.
Ocugen Doses First Patient in Phase 1 Trial of OCU200 for Diabetic Macular Edema
Ocugen has initiated a Phase 1 clinical trial for OCU200, a novel integrin-targeting biologic, in patients with diabetic macular edema (DME).